SlideShare a Scribd company logo
1 of 41
MANAGING NEW
REQUIREMENTS
FOR EO REGIME
Q1 MDR 2019
17 July 2019
Erik Vollebregt
www.axonadvocaten.nl
Agenda
• Territorial scope of MDR / IVDR economic
operator regulation
• Who is economic operator?
• Economic operators new stuff
• Pooling of EO resources in corporate
groups
• Third parties: repacking/relabelling, parts &
components
• Authorised representative
• Brexit
• Bonus slides on EO agreement drafting and
negotiation
EO status
• With most of the technical
documentation and QMS
remediation over, companies
turn to EO remediation and
everybody is figuring this out at
the moment
• CAMD guidance promised but
lacking as usual
• No significant engagement with
independent distributors seems
to be happening in the market
as far as I can see
Economic operator territorial
scope
Essential Tools for MDR / IVDR
supply chain
• MDR / IVDR
• Blue Guide 2016
• Commission informative notice on placing on the market
• Decision 768/2008 (rumors that it will be revised)
Where does this apply?
Where does this apply?
• Note:
• EEA is “Union” for the purpose of the Blue Guide
• Turkey, Switzerland and – possibly soon the UK after Brexit end
March 2019 – are “third countries” which only count as Union if
the instrument in place says so explicitly
• Distinction between Union and third countries is relevant for
key concepts in MDR relating to economic operators (e.g.
placing on the market, importer and AR)
• Turkey is implementing
• Switzerland still in suspense about what the new Mutual
Recognition Agreement will look like
• Does not make devices available on own behalf
• Places non-imported
devices on the
market
• Places imported
devices on the
market
• Established in the
Union
• Makes devices
available
• Can be
manufacturer (or
not) under art. 16
conditions (branded
distribution
• May put devices
into service
Authorised
Representative
Manufacturer Importer Distributor
Clearance, logistics and storage providers
How does this apply?
• Has general EO obligations (e.g. UDI)
System integrator /
procedure pack
steriliser
How does this apply?
Understanding of concepts of “placing on the market” and “making
available” crucial for EO characterisation
Placing on the market
• first transfer of a device from the manufacturing stage into the Union
distribution chain after final quality control release as finished goods
(includes packaging or labelling); and
• the device must be freely available for supply or final use within the
Union supply chain (customs cleared and intent to distribute in Union)
Making available
• device must be supplied for distribution, consumption or use in the
Union in the course of a commercial activity, either for payment or free of
charge
• Implies offer or agreement, physical handover not required
Challenges (just a few)
• What the heck is placing on the market and making available?
• How to set up the AR in view of arm’s length placement because of
product liability risk?
• Importer labelling – how, what, where?
• How to equip/operationalise the PRRC?
• What is ‘verification’ and ‘consider or have reason to believe’?
• How to pool resources to be made available to an intra-group chain of
EOs? Can AR and MFR share PRRC resource etc.?
• How to cooperate between EOs on overlapping responsibilities?
• How to work with EO obligations in soft transition periods (2020-2024
MDR and 2022-2024 IVDR)
• Dealing with third parties that turn out to be importers or distributors (e.g.
fulfilment houses – see Blue Guide)
• Systems integrators / kitters / sterilisers awareness of EO obligations
• The article 23 component manufacturer as new EO
Obligations economic operators
• Name on device
• CE +DOC
• GSPR
• UDI
• PRRC
• Name on device
• Check Eudamed
• Register of
complaints
• Check DoC + cert
• Assist with corr.
action.
• Safeguard storage
conditions
• Assist authorities
• Not make available if
conformity
compromised
• Forward complaints
• Safeguard storage
conditions
• Assist with corr.
action.
• Assist authorities
• Not make available
if conformity
compromised
Authorised
Representative
Verify compliance:
• CE +DoC
• AR assigned
• Labeling
• UDI
Verify compliance:
• CE +DoC
• IFU present
• Importer details
added
• UDI
Manufacturer Importer Distributor
Division of responsibilities
• Agreements in supply chain should
account for manufacturer’s interests
regarding each line in this diagram
New stuff in chapter II compared to
Decision 768/2008 re EOs
• Includes some provisions that create ‘new’ EOs (system integrator and
procedure pack assembler (art. 2 (35) MDR), new liability
• Cases in which obligations of manufacturers apply to importers,
distributors or other persons (art. 16)
• Repacking / relabeling regime – medicinal products modelled but
stricter than CJEU Servoprax judgment
• AR jointly and severally product liable (art. 11)
• PRRC (art. 15)
• DOC to be updated continuously and translated in languages required
by the Member State(s) in which the device is made available (art. 19)
• Cases where parts / components suppliers must validate part /
component or be manufacturer of device (art. 23)
New stuff in Blue Guide that is
often overlooked
• The role of fulfilment houses (FHs) as service provider to EOs (section
3.4)
• If their activities “go beyond those of parcel service providers that
provide clearance services, sorting, transport and delivery of
parcels […] they should be considered as distributors and should
fulfil the corresponding legal responsibilities.”
• Many medical devices companies find that their FHs are not ‘neutral’
service providers but MDR regulated distributors ex art. 14 MDR as a
result of the services they provide
Economic operators resource
sharing within company
What resources can be shared in
corporate group with internal EOs?
• The EO regime
• does not translate well to large companies that have multiple EOs
under the same joint control
• makes amending your supply chain contracts a good idea
• Can a company pool resources between various EOs?
• Yes, but EO concerned always remains responsible
• Use internal quality agreements or QMS procedures to enable
internal verification and audit
• Make sure to establish entities/persons in EU where this is required
• Some roles can be combined in one EU legal entity, some cannot
and some require careful consideration (i.e. AR and any other role)
What resources can be shared in
corporate group with internal EOs?
Authorised representative
Authorised representative
• Big changes for authorised representatives, both ‘in-house’ and external
• Implementation of AR MEDDEV
• Prescriptive rules for AR mandate and contract – like notified bodies ARs
are recruited into market surveillance
• AR must provide information, cooperate in investigation and verify that
appropriate conformity assessment procedure has been carried out by
the manufacturer
• AR must have person responsible for regulatory compliance
• Problematic:
• terminate the mandate if the manufacturer acts contrary to his
obligations
• In case of termination, notify CA and Notified Body of termination
and reasons for termination
Authorised representative
• Companies with internal AR wonder what the required level of non-
compliance is for mandatory termination under article 11 (3) (h)?
• Internal escalation and remediation process
• Can also be used for external AR agreement
PRRC
PRRC requirements
• Article 15 MDR:
• Manufacturer must employ one
• AR and/or micro/small undertaking should contract one
• PRRC role can be shared between several persons
• MDCG Guidance 2019-7:
• PRRC for the manufacturer and AR cannot be the same person
• PRRC for the AR must be located in the EU
• PRRC qualifications must be proven by demonstrated member
state equivalency
• guidance provides a level of detail with regard to the cross-links
between the manufacturer responsibilities under article 10
MDR/IVDR and the PRRC minimum responsibilities set out in
article 15 (3) MDR/IVDR
Brexit
Brexit
• Nobody has the answer in the UK and politics
are all over the place
• At present, uncertain whether no deal Brexit or
not and if deal what it will look like
• Halloween Brexit deadline now (31
October 2019)
• Most MFRs do not have a solid Brexit plan
in case of hard Brexit
• Member states still caution companies to
prepare for no deal scenario
• Plan be can be ramping up production to
build bridging stock
• Ensure EU 27 notified body, AR and
importer
#Brexit
preparations
• Consequences for economic operators (unless the instrument between
UK and EU provides differently) in case of ‘hard’ Brexit because UK is no
longer “Union” so
• Manufacturer in UK is not in Union, needs importer and AR for EU
• Importer and AR for EU purposes cannot be based there
• UK can not / no longer have notified bodies
• For current directives (AIMDD, MDD, IVDD)
• For MDR and IVDR
• Transition to EU27 NB before withdrawal date (end March 2019)
• All CE certificates granted by UK notified bodies will be invalid in the
EU per withdrawal date because European law ceases to apply and
UK notifications of notified bodies become void
• Unsure if CAMD orphaning procedure applies to this
Third party parts, components and
repacking/relabeling
Third parties: parts & components
Article 23 MDR / 20 IVDR: “1. Any natural or legal person who makes
available on the market an article intended specifically to replace an
identical or similar integral part or component of a device that is defective
or worn in order to maintain or re-establish the function of the device
without changing its performance or safety characteristics or its intended
purpose, shall ensure that the article does not adversely affect the safety
and performance of the device. Supporting evidence shall be kept available
to the competent authorities of the Member States.
2. An article that is intended specifically to replace a part or component of a
device and that significantly changes the performance or safety
characteristics or the intended purpose of the device shall be considered
as a device and shall meet the requirements laid down in this Regulation.
Third parties: parts & components
• Non-OEM replacement parts and components must have supporting
evidence that they do not adversely affect the safety and performance of
the device
• Standard of supporting evidence? Criterion presumes a validation
• Is OEM obliged to cooperate in validation?
• Non-OEM enhancement parts are devices
• How will that work in practice? – accessory type evaluation?
• Is manufacturer obliged to development of supporting evidence for
competing non-OEM parts/components?
• Printer cartridge competition law cases
Third parties: repacking &
relabelling
• Basically pharma repacking case law written down for devices
• Strangely enough stricter regime than outcome of the EU Court
Servoprax case (C-277/15)
• Article 16 (2) MDR / 15 (2) IVDR:
• Translation of IFU and other information and repacking do not
make someone a manufacturer
• Indicated person responsible for activity on the pack or
accompanying document
• Have notified body blessed QMS and vigilance for activity
• But blessed under what standard / CS / criteria?
• Reporting and mock-up to manufacturer and NCA for each time
repacked / relabelled device is made available
Thanks for your attention!
Erik Vollebregt
Axon Lawyers
Piet Heinkade 183
1019 HC Amsterdam
T +31 88 650 6500
M +31 6 47 180 683
E erik.vollebregt@axonlawyers.com
@meddevlegal
B http://medicaldeviceslegal.com
READ MY BLOG:
http://medicaldeviceslegal.com
Bonus slides on EO agreement
drafting and negotiation
Major overlaps in EO obligations for
example in PMS and vigilance
• Account for overlaps in your supply, distribution, agency, etc. agreements
Post-Market Surveillance (PMS) & Vigilance EU MFR Non-EU
MFR
AR Importer Distributor
Complaint communication within supply chain
Keep register of complaints, non-conforming
devices complaints, recalls, withdrawals
Inform manufacturer, AR, importer about device
non-conformity
Vigilance System
Vigilance Reporting2
Provide documentation demonstrating device
compliance to Competent Authority (CA)
Provide product samples free of charge to CA
Provide information on serious risks of device
to authorities
Provide Notified Body with information on
serious risk devices
Implement FSCAs
Cooperation with authorities on FSCAs
Overlaps in conformity obligations
Device conformity MFR Non-EU
MFR
AR Importer Distributor
QMS pursuant to MDR / IVDR (Article 10 (9))
Person responsible for regulatory compliance
QMS according to Article 16 (3) 2nd
subparagraph as applicable
Ensure proper device storage and transport
Conformity assessment including CE-certificate
Verification of appropriate conformity
assessment procedure
Verify CE-marking
Keep copy of CE-certificate
UDI assignment
Verify UDI assignment
Draw up Technical Documentation and keep it
available 10/15 years
Verification of Technical Documentation
availability
Keep copy of Technical Documentation
Draw up of Declaration of Conformity and keep it
available 10/15 years
Verification of availability of Declaration of
Conformity
Keep Declaration of Conformity available
• More sets of overlaps like this, e.g. in labeling, UDI
and (product) liability
What must be looked at in IMP
agreement from MDR perspective?
• Verification obligations
• How to implement verification obligations?
• Define when the IMP has considers or has reason to believe that a
device is not in conformity with MDR requirements
• Can MFR intervene / be informed before IMP notifies authorities
of device presents a serious risk or is a falsified device?
• Labeling and registration obligations
• How will IMP label? (not obscure any information on the label
provided by the manufacturer) – information exchange
• Work with UDI and Eudamed
• Safeguard transport and storage conditions
• How will IMP do this? Consequences?
What must be looked at in IMP
agreement from MDR perspective?
• Register of complaints
• IMP must keep a register of complaints, of non-conforming devices
and of recalls and withdrawals, and provide the manufacturer,
authorised representative and distributors with any information
requested by them, in order to allow them to investigate complaints –
how will this work in practice?
• Corrective action of IMPs
• When is there a serious risk that warrants IMP to notify Notified Body
and CA?
• What action will take IMP? What information must be given to MFR
beforehand? What consequences if IMP is wrong in implementing
corrective action?
What must be looked at in IMP
agreement from MDR perspective?
• Vigilance obligations of IMP and information sharing
• Share with MFR complaints or reports from healthcare professionals,
patients or users about suspected incidents - how will that be
implemented and what is IMP confidential information?
• DOC and certs on file
• keep a copy of the EU declaration of conformity and, if applicable, a
copy of any relevant certificate, including any amendments and
supplements – how does the information exchange work?
• Cooperation with authorities
• Importers shall cooperate with competent authorities, at the latter’s
request, on any action taken to eliminate / mitigate – what
information and cooperation with MFR?
What must be looked at in DIS
agreement from MDR perspective?
• General obligation – due care
• DIS must act with due care in relation to the requirements applicable
– what does this mean in terms of care vis-à-vis manufacturer?
• Verification obligations
• How to implement verification obligations?
• Define when the DIS has considers or has reason to believe that a
device is not in conformity with MDR requirements
• Can MFR intervene / be informed before DIS notifies authorities
of device presents a serious risk or is a falsified device?
• Safeguard transport and storage conditions
• How will IMP do this? Consequences?
What must be looked at in DIS
agreement from MDR perspective?
• Corrective action of DIS
• When is there a serious risk that warrants DIS to notify Notified Body
and CA?
• What action will take DIS? What information must be given to MFR
beforehand? What consequences if DIS is wrong in implementing
corrective action?
• Vigilance obligations of DIS and information sharing
• Share with MFR and IMP complaints or reports from healthcare
professionals, patients or users about suspected incidents - how will
that be implemented and what is DIS confidential information?
What must be looked at in DIS
agreement from MDR perspective?
• Cooperation with authorities
• Importers shall cooperate with competent authorities, at the latter’s
request, on any action taken to eliminate / mitigate – what
information and cooperation with MFR?
• Registration obligations, traceability and UDI
• How will MFR and DIS cooperate ‘to achieve an appropriate level of
traceability of devices’
• National registration obligations (transfer of registrations etc)
Review your distribution
agreements
• Good clause / bad clause?
• Hint: drafted in the assumption that the distributor does not have any
autonomous obligations

More Related Content

What's hot

Economic operators and post market surveillance under the proposed EU medicin...
Economic operators and post market surveillance under the proposed EU medicin...Economic operators and post market surveillance under the proposed EU medicin...
Economic operators and post market surveillance under the proposed EU medicin...
Erik Vollebregt
 
Chapter VIII: Technical barriers to trade chapter
Chapter VIII: Technical barriers to trade chapterChapter VIII: Technical barriers to trade chapter
Chapter VIII: Technical barriers to trade chapter
Balo English
 
Lecture 10 ib 404 institutional framework for international business
Lecture 10 ib 404 institutional framework for international businessLecture 10 ib 404 institutional framework for international business
Lecture 10 ib 404 institutional framework for international business
Mahir Jawad
 

What's hot (20)

Q1 medical device packaging conference 10 november 2020
Q1 medical device packaging conference 10 november 2020Q1 medical device packaging conference 10 november 2020
Q1 medical device packaging conference 10 november 2020
 
Advamed Med Tech 2019 countdown presentation
Advamed Med Tech 2019 countdown presentationAdvamed Med Tech 2019 countdown presentation
Advamed Med Tech 2019 countdown presentation
 
EU MDR Annex I Simplified
EU MDR Annex I SimplifiedEU MDR Annex I Simplified
EU MDR Annex I Simplified
 
Regulation of Economic Operators under the MDR and IVDR
Regulation of Economic Operators under the MDR and IVDRRegulation of Economic Operators under the MDR and IVDR
Regulation of Economic Operators under the MDR and IVDR
 
Liability insurance requirements under the new EU Medical Devices Regulation ...
Liability insurance requirements under the new EU Medical Devices Regulation ...Liability insurance requirements under the new EU Medical Devices Regulation ...
Liability insurance requirements under the new EU Medical Devices Regulation ...
 
New legal obligations and liability under MDR and IVDR
New legal obligations and liability under MDR and IVDRNew legal obligations and liability under MDR and IVDR
New legal obligations and liability under MDR and IVDR
 
Economic operators and post market surveillance under the proposed EU medicin...
Economic operators and post market surveillance under the proposed EU medicin...Economic operators and post market surveillance under the proposed EU medicin...
Economic operators and post market surveillance under the proposed EU medicin...
 
MDR aspects for the sterilisation industry
MDR aspects for the sterilisation industryMDR aspects for the sterilisation industry
MDR aspects for the sterilisation industry
 
The New EU MDR and What You Need to Know
The New EU MDR and What You Need to KnowThe New EU MDR and What You Need to Know
The New EU MDR and What You Need to Know
 
Chapter VIII: Technical barriers to trade chapter
Chapter VIII: Technical barriers to trade chapterChapter VIII: Technical barriers to trade chapter
Chapter VIII: Technical barriers to trade chapter
 
Lecture 10 ib 404 institutional framework for international business
Lecture 10 ib 404 institutional framework for international businessLecture 10 ib 404 institutional framework for international business
Lecture 10 ib 404 institutional framework for international business
 
7 Steps - How to Get a CE Marking Certification for Medical Devices?
7 Steps - How to Get a CE Marking Certification for Medical Devices?7 Steps - How to Get a CE Marking Certification for Medical Devices?
7 Steps - How to Get a CE Marking Certification for Medical Devices?
 
Technical Barriers to Trade - Dianne Lalla-Rodrigues - Director of the Antigu...
Technical Barriers to Trade - Dianne Lalla-Rodrigues - Director of the Antigu...Technical Barriers to Trade - Dianne Lalla-Rodrigues - Director of the Antigu...
Technical Barriers to Trade - Dianne Lalla-Rodrigues - Director of the Antigu...
 
Agreement on Technical Barriers to Trade
Agreement on Technical Barriers to TradeAgreement on Technical Barriers to Trade
Agreement on Technical Barriers to Trade
 
Quality Metrics Program - Impact & Challenges
Quality Metrics Program - Impact & ChallengesQuality Metrics Program - Impact & Challenges
Quality Metrics Program - Impact & Challenges
 
Strategies for Expediting Export Control Licensing
Strategies for Expediting Export Control LicensingStrategies for Expediting Export Control Licensing
Strategies for Expediting Export Control Licensing
 
UK Export Controls: 8 Steps For Compliance
UK Export Controls: 8 Steps For ComplianceUK Export Controls: 8 Steps For Compliance
UK Export Controls: 8 Steps For Compliance
 
Changes in device classification under the EU Medical Devices and In Vitro Di...
Changes in device classification under the EU Medical Devices and In Vitro Di...Changes in device classification under the EU Medical Devices and In Vitro Di...
Changes in device classification under the EU Medical Devices and In Vitro Di...
 
UK Export Controls: Taking a Strategic Approach
UK Export Controls: Taking a Strategic ApproachUK Export Controls: Taking a Strategic Approach
UK Export Controls: Taking a Strategic Approach
 
UK Export Controls: Technology
UK Export Controls: TechnologyUK Export Controls: Technology
UK Export Controls: Technology
 

Similar to Managing New Requirement for Economic Operator Regime

AIFMD Surgery Webinar Depositaries
AIFMD Surgery Webinar DepositariesAIFMD Surgery Webinar Depositaries
AIFMD Surgery Webinar Depositaries
Cordium
 
Eu hot topics alliance presentation 2
Eu hot topics alliance presentation 2Eu hot topics alliance presentation 2
Eu hot topics alliance presentation 2
Erik Vollebregt
 
Eu hot topics alliance presentation
Eu hot topics alliance presentationEu hot topics alliance presentation
Eu hot topics alliance presentation
Erik Vollebregt
 
Eu hot topics alliance presentation 3
Eu hot topics alliance presentation 3Eu hot topics alliance presentation 3
Eu hot topics alliance presentation 3
Erik Vollebregt
 

Similar to Managing New Requirement for Economic Operator Regime (20)

Economic operators under the MDR and IVDR
Economic operators under the MDR and IVDREconomic operators under the MDR and IVDR
Economic operators under the MDR and IVDR
 
Q1 Medical Devices Regulation - practical consequences for manufacturers
Q1 Medical Devices Regulation - practical consequences for manufacturersQ1 Medical Devices Regulation - practical consequences for manufacturers
Q1 Medical Devices Regulation - practical consequences for manufacturers
 
MD project seminar how to manage the maid short version
MD project seminar how to manage the maid short versionMD project seminar how to manage the maid short version
MD project seminar how to manage the maid short version
 
AIFMD Surgery Webinar Depositaries
AIFMD Surgery Webinar DepositariesAIFMD Surgery Webinar Depositaries
AIFMD Surgery Webinar Depositaries
 
Eu hot topics alliance presentation 2
Eu hot topics alliance presentation 2Eu hot topics alliance presentation 2
Eu hot topics alliance presentation 2
 
Eu hot topics alliance presentation
Eu hot topics alliance presentationEu hot topics alliance presentation
Eu hot topics alliance presentation
 
Eu hot topics alliance presentation 3
Eu hot topics alliance presentation 3Eu hot topics alliance presentation 3
Eu hot topics alliance presentation 3
 
Rationing offshore wind in a post-subsidy world
Rationing offshore wind in a post-subsidy worldRationing offshore wind in a post-subsidy world
Rationing offshore wind in a post-subsidy world
 
EU regulatory agenda 2018 2019
EU regulatory agenda 2018 2019EU regulatory agenda 2018 2019
EU regulatory agenda 2018 2019
 
Recent and future developments in UDI for medical devices in the EU
Recent and future developments in UDI for medical devices in the EURecent and future developments in UDI for medical devices in the EU
Recent and future developments in UDI for medical devices in the EU
 
Chappuis Halder - EU Benchmark Regulation threepager - May 2016
Chappuis Halder - EU Benchmark Regulation threepager - May 2016Chappuis Halder - EU Benchmark Regulation threepager - May 2016
Chappuis Halder - EU Benchmark Regulation threepager - May 2016
 
Brexit Questions & Answers
Brexit Questions & AnswersBrexit Questions & Answers
Brexit Questions & Answers
 
A future for regulation in the UK
A future for regulation in the UKA future for regulation in the UK
A future for regulation in the UK
 
PPT, L Kojnok, EC, Third ENP East public procurement conference, Tbilisi, 6 N...
PPT, L Kojnok, EC, Third ENP East public procurement conference, Tbilisi, 6 N...PPT, L Kojnok, EC, Third ENP East public procurement conference, Tbilisi, 6 N...
PPT, L Kojnok, EC, Third ENP East public procurement conference, Tbilisi, 6 N...
 
Informa Eudamed update 29 january 2014
Informa Eudamed update 29 january 2014Informa Eudamed update 29 january 2014
Informa Eudamed update 29 january 2014
 
New legal obligations under MDR and IVDR
New legal obligations under MDR and IVDRNew legal obligations under MDR and IVDR
New legal obligations under MDR and IVDR
 
EFPIA Pharma Transparency Code - EFPIA Disclosure Code
EFPIA Pharma Transparency Code - EFPIA Disclosure CodeEFPIA Pharma Transparency Code - EFPIA Disclosure Code
EFPIA Pharma Transparency Code - EFPIA Disclosure Code
 
Post marketing surveillance april 2011
Post marketing surveillance april 2011Post marketing surveillance april 2011
Post marketing surveillance april 2011
 
Unraveling EU regulation for US Managers - Bovill New York Briefing
Unraveling EU regulation for US Managers - Bovill New York BriefingUnraveling EU regulation for US Managers - Bovill New York Briefing
Unraveling EU regulation for US Managers - Bovill New York Briefing
 
European market infrastructure regulation (emir) - Quick Overview
European market infrastructure regulation (emir) - Quick OverviewEuropean market infrastructure regulation (emir) - Quick Overview
European market infrastructure regulation (emir) - Quick Overview
 

More from Erik Vollebregt

More from Erik Vollebregt (14)

Easy medical devices podcast self tests ivdr
Easy medical devices podcast self tests ivdrEasy medical devices podcast self tests ivdr
Easy medical devices podcast self tests ivdr
 
MDR and class I medical devices presentation
MDR and class I medical devices presentationMDR and class I medical devices presentation
MDR and class I medical devices presentation
 
Legal and regulatory developments in precision medicine and diagnostic devices
Legal and regulatory developments in precision medicine and diagnostic devicesLegal and regulatory developments in precision medicine and diagnostic devices
Legal and regulatory developments in precision medicine and diagnostic devices
 
GDPR and eHealth for the pharma industry (VFenR presentation)
GDPR and eHealth for the pharma industry (VFenR presentation)GDPR and eHealth for the pharma industry (VFenR presentation)
GDPR and eHealth for the pharma industry (VFenR presentation)
 
VZI jaarcongres: de MDR en IVDR - de impact in de medische techniek
VZI jaarcongres: de MDR en IVDR - de impact in de medische techniekVZI jaarcongres: de MDR en IVDR - de impact in de medische techniek
VZI jaarcongres: de MDR en IVDR - de impact in de medische techniek
 
NEN symposium on Medical Devices and IVD Regulation
NEN symposium on Medical Devices and IVD RegulationNEN symposium on Medical Devices and IVD Regulation
NEN symposium on Medical Devices and IVD Regulation
 
Advamed EU MDR and IVDR panel presentation
Advamed EU MDR and IVDR panel presentationAdvamed EU MDR and IVDR panel presentation
Advamed EU MDR and IVDR panel presentation
 
Use of left over samples under the IVDR and GDPR
Use of left over samples under the IVDR and GDPRUse of left over samples under the IVDR and GDPR
Use of left over samples under the IVDR and GDPR
 
Trends in EU regulation of software as medical device
Trends in EU regulation of software as medical deviceTrends in EU regulation of software as medical device
Trends in EU regulation of software as medical device
 
Legal issues relating to clinical investigation with medical devices
Legal issues relating to clinical investigation with medical devicesLegal issues relating to clinical investigation with medical devices
Legal issues relating to clinical investigation with medical devices
 
3D medtech printing under EU Medical Devices Directive and under future Medic...
3D medtech printing under EU Medical Devices Directive and under future Medic...3D medtech printing under EU Medical Devices Directive and under future Medic...
3D medtech printing under EU Medical Devices Directive and under future Medic...
 
EU cybersecurity requirements under current and future medical devices regula...
EU cybersecurity requirements under current and future medical devices regula...EU cybersecurity requirements under current and future medical devices regula...
EU cybersecurity requirements under current and future medical devices regula...
 
Transparency under the new MDR and IVDR
Transparency under the new MDR and IVDRTransparency under the new MDR and IVDR
Transparency under the new MDR and IVDR
 
Advamed MDR IVDR update
Advamed MDR IVDR updateAdvamed MDR IVDR update
Advamed MDR IVDR update
 

Recently uploaded

ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
jvomprakash
 
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptxINTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx
AnushriSrivastav
 
Cytotec 200mcg tab in Riyadh (+919101817206// Get Abortion Pills in Saudi Arabia
Cytotec 200mcg tab in Riyadh (+919101817206// Get Abortion Pills in Saudi ArabiaCytotec 200mcg tab in Riyadh (+919101817206// Get Abortion Pills in Saudi Arabia
Cytotec 200mcg tab in Riyadh (+919101817206// Get Abortion Pills in Saudi Arabia
jaanualu31
 
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
icha27638
 
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Levi Shapiro
 
Liver Function Test.ppt MBBS A healthcare provider draws a small amoun
Liver Function Test.ppt MBBS A healthcare provider draws a small amounLiver Function Test.ppt MBBS A healthcare provider draws a small amoun
Liver Function Test.ppt MBBS A healthcare provider draws a small amoun
ssuser77fe3b
 

Recently uploaded (20)

Leading large scale change: a life at the interface between theory and practice
Leading large scale change: a life at the interface between theory and practiceLeading large scale change: a life at the interface between theory and practice
Leading large scale change: a life at the interface between theory and practice
 
Mike Lowe’s cancer fight lowe strong shirt
Mike Lowe’s cancer fight lowe strong shirtMike Lowe’s cancer fight lowe strong shirt
Mike Lowe’s cancer fight lowe strong shirt
 
ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
 
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptxINTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx
 
Unlock the Secrets to Optimizing Ambulatory Operations Efficiency and Change ...
Unlock the Secrets to Optimizing Ambulatory Operations Efficiency and Change ...Unlock the Secrets to Optimizing Ambulatory Operations Efficiency and Change ...
Unlock the Secrets to Optimizing Ambulatory Operations Efficiency and Change ...
 
clostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptx
clostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptxclostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptx
clostridiumbotulinum- BY Muzammil Ahmed Siddiqui.pptx
 
Technology transfer documentation and strategies
Technology transfer documentation and strategiesTechnology transfer documentation and strategies
Technology transfer documentation and strategies
 
Leadership Style - Code and Rapid Response Workshop
Leadership Style - Code and Rapid Response WorkshopLeadership Style - Code and Rapid Response Workshop
Leadership Style - Code and Rapid Response Workshop
 
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
 
Session-3-Promoting-Breastfeeding-During-Pregnancy.ppt
Session-3-Promoting-Breastfeeding-During-Pregnancy.pptSession-3-Promoting-Breastfeeding-During-Pregnancy.ppt
Session-3-Promoting-Breastfeeding-During-Pregnancy.ppt
 
Making change happen: learning from "positive deviancts"
Making change happen: learning from "positive deviancts"Making change happen: learning from "positive deviancts"
Making change happen: learning from "positive deviancts"
 
Cytotec 200mcg tab in Riyadh (+919101817206// Get Abortion Pills in Saudi Arabia
Cytotec 200mcg tab in Riyadh (+919101817206// Get Abortion Pills in Saudi ArabiaCytotec 200mcg tab in Riyadh (+919101817206// Get Abortion Pills in Saudi Arabia
Cytotec 200mcg tab in Riyadh (+919101817206// Get Abortion Pills in Saudi Arabia
 
VIP ℂall Girls Prabhadevi Point 8250077686 WhatsApp: Me All Time Serviℂe Avai...
VIP ℂall Girls Prabhadevi Point 8250077686 WhatsApp: Me All Time Serviℂe Avai...VIP ℂall Girls Prabhadevi Point 8250077686 WhatsApp: Me All Time Serviℂe Avai...
VIP ℂall Girls Prabhadevi Point 8250077686 WhatsApp: Me All Time Serviℂe Avai...
 
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
Obat aborsi Jakarta Timur Wa 081225888346 Jual Obat aborsi Cytotec asli Di Ja...
 
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
 
Young & Hot ℂall Girls Kolkata 8250077686 WhatsApp Number Best Rates of Kolka...
Young & Hot ℂall Girls Kolkata 8250077686 WhatsApp Number Best Rates of Kolka...Young & Hot ℂall Girls Kolkata 8250077686 WhatsApp Number Best Rates of Kolka...
Young & Hot ℂall Girls Kolkata 8250077686 WhatsApp Number Best Rates of Kolka...
 
Liver Function Test.ppt MBBS A healthcare provider draws a small amoun
Liver Function Test.ppt MBBS A healthcare provider draws a small amounLiver Function Test.ppt MBBS A healthcare provider draws a small amoun
Liver Function Test.ppt MBBS A healthcare provider draws a small amoun
 
mHealth Israel_Healthcare Finance and M&A- What Comes Next
mHealth Israel_Healthcare Finance and M&A- What Comes NextmHealth Israel_Healthcare Finance and M&A- What Comes Next
mHealth Israel_Healthcare Finance and M&A- What Comes Next
 
Young & Hot ℂall Girls Mumbai 8250077686 WhatsApp Number Best Rates of Mumbai...
Young & Hot ℂall Girls Mumbai 8250077686 WhatsApp Number Best Rates of Mumbai...Young & Hot ℂall Girls Mumbai 8250077686 WhatsApp Number Best Rates of Mumbai...
Young & Hot ℂall Girls Mumbai 8250077686 WhatsApp Number Best Rates of Mumbai...
 
Session-5-Birthing-Practices-Breastfeeding (1).ppt
Session-5-Birthing-Practices-Breastfeeding (1).pptSession-5-Birthing-Practices-Breastfeeding (1).ppt
Session-5-Birthing-Practices-Breastfeeding (1).ppt
 

Managing New Requirement for Economic Operator Regime

  • 1. MANAGING NEW REQUIREMENTS FOR EO REGIME Q1 MDR 2019 17 July 2019 Erik Vollebregt www.axonadvocaten.nl
  • 2. Agenda • Territorial scope of MDR / IVDR economic operator regulation • Who is economic operator? • Economic operators new stuff • Pooling of EO resources in corporate groups • Third parties: repacking/relabelling, parts & components • Authorised representative • Brexit • Bonus slides on EO agreement drafting and negotiation
  • 3. EO status • With most of the technical documentation and QMS remediation over, companies turn to EO remediation and everybody is figuring this out at the moment • CAMD guidance promised but lacking as usual • No significant engagement with independent distributors seems to be happening in the market as far as I can see
  • 5. Essential Tools for MDR / IVDR supply chain • MDR / IVDR • Blue Guide 2016 • Commission informative notice on placing on the market • Decision 768/2008 (rumors that it will be revised)
  • 7. Where does this apply? • Note: • EEA is “Union” for the purpose of the Blue Guide • Turkey, Switzerland and – possibly soon the UK after Brexit end March 2019 – are “third countries” which only count as Union if the instrument in place says so explicitly • Distinction between Union and third countries is relevant for key concepts in MDR relating to economic operators (e.g. placing on the market, importer and AR) • Turkey is implementing • Switzerland still in suspense about what the new Mutual Recognition Agreement will look like
  • 8. • Does not make devices available on own behalf • Places non-imported devices on the market • Places imported devices on the market • Established in the Union • Makes devices available • Can be manufacturer (or not) under art. 16 conditions (branded distribution • May put devices into service Authorised Representative Manufacturer Importer Distributor Clearance, logistics and storage providers How does this apply? • Has general EO obligations (e.g. UDI) System integrator / procedure pack steriliser
  • 9. How does this apply? Understanding of concepts of “placing on the market” and “making available” crucial for EO characterisation Placing on the market • first transfer of a device from the manufacturing stage into the Union distribution chain after final quality control release as finished goods (includes packaging or labelling); and • the device must be freely available for supply or final use within the Union supply chain (customs cleared and intent to distribute in Union) Making available • device must be supplied for distribution, consumption or use in the Union in the course of a commercial activity, either for payment or free of charge • Implies offer or agreement, physical handover not required
  • 10. Challenges (just a few) • What the heck is placing on the market and making available? • How to set up the AR in view of arm’s length placement because of product liability risk? • Importer labelling – how, what, where? • How to equip/operationalise the PRRC? • What is ‘verification’ and ‘consider or have reason to believe’? • How to pool resources to be made available to an intra-group chain of EOs? Can AR and MFR share PRRC resource etc.? • How to cooperate between EOs on overlapping responsibilities? • How to work with EO obligations in soft transition periods (2020-2024 MDR and 2022-2024 IVDR) • Dealing with third parties that turn out to be importers or distributors (e.g. fulfilment houses – see Blue Guide) • Systems integrators / kitters / sterilisers awareness of EO obligations • The article 23 component manufacturer as new EO
  • 12. • Name on device • CE +DOC • GSPR • UDI • PRRC • Name on device • Check Eudamed • Register of complaints • Check DoC + cert • Assist with corr. action. • Safeguard storage conditions • Assist authorities • Not make available if conformity compromised • Forward complaints • Safeguard storage conditions • Assist with corr. action. • Assist authorities • Not make available if conformity compromised Authorised Representative Verify compliance: • CE +DoC • AR assigned • Labeling • UDI Verify compliance: • CE +DoC • IFU present • Importer details added • UDI Manufacturer Importer Distributor
  • 13. Division of responsibilities • Agreements in supply chain should account for manufacturer’s interests regarding each line in this diagram
  • 14. New stuff in chapter II compared to Decision 768/2008 re EOs • Includes some provisions that create ‘new’ EOs (system integrator and procedure pack assembler (art. 2 (35) MDR), new liability • Cases in which obligations of manufacturers apply to importers, distributors or other persons (art. 16) • Repacking / relabeling regime – medicinal products modelled but stricter than CJEU Servoprax judgment • AR jointly and severally product liable (art. 11) • PRRC (art. 15) • DOC to be updated continuously and translated in languages required by the Member State(s) in which the device is made available (art. 19) • Cases where parts / components suppliers must validate part / component or be manufacturer of device (art. 23)
  • 15. New stuff in Blue Guide that is often overlooked • The role of fulfilment houses (FHs) as service provider to EOs (section 3.4) • If their activities “go beyond those of parcel service providers that provide clearance services, sorting, transport and delivery of parcels […] they should be considered as distributors and should fulfil the corresponding legal responsibilities.” • Many medical devices companies find that their FHs are not ‘neutral’ service providers but MDR regulated distributors ex art. 14 MDR as a result of the services they provide
  • 17. What resources can be shared in corporate group with internal EOs? • The EO regime • does not translate well to large companies that have multiple EOs under the same joint control • makes amending your supply chain contracts a good idea • Can a company pool resources between various EOs? • Yes, but EO concerned always remains responsible • Use internal quality agreements or QMS procedures to enable internal verification and audit • Make sure to establish entities/persons in EU where this is required • Some roles can be combined in one EU legal entity, some cannot and some require careful consideration (i.e. AR and any other role)
  • 18. What resources can be shared in corporate group with internal EOs?
  • 20. Authorised representative • Big changes for authorised representatives, both ‘in-house’ and external • Implementation of AR MEDDEV • Prescriptive rules for AR mandate and contract – like notified bodies ARs are recruited into market surveillance • AR must provide information, cooperate in investigation and verify that appropriate conformity assessment procedure has been carried out by the manufacturer • AR must have person responsible for regulatory compliance • Problematic: • terminate the mandate if the manufacturer acts contrary to his obligations • In case of termination, notify CA and Notified Body of termination and reasons for termination
  • 21. Authorised representative • Companies with internal AR wonder what the required level of non- compliance is for mandatory termination under article 11 (3) (h)? • Internal escalation and remediation process • Can also be used for external AR agreement
  • 22. PRRC
  • 23. PRRC requirements • Article 15 MDR: • Manufacturer must employ one • AR and/or micro/small undertaking should contract one • PRRC role can be shared between several persons • MDCG Guidance 2019-7: • PRRC for the manufacturer and AR cannot be the same person • PRRC for the AR must be located in the EU • PRRC qualifications must be proven by demonstrated member state equivalency • guidance provides a level of detail with regard to the cross-links between the manufacturer responsibilities under article 10 MDR/IVDR and the PRRC minimum responsibilities set out in article 15 (3) MDR/IVDR
  • 25. Brexit • Nobody has the answer in the UK and politics are all over the place • At present, uncertain whether no deal Brexit or not and if deal what it will look like • Halloween Brexit deadline now (31 October 2019) • Most MFRs do not have a solid Brexit plan in case of hard Brexit • Member states still caution companies to prepare for no deal scenario • Plan be can be ramping up production to build bridging stock • Ensure EU 27 notified body, AR and importer
  • 26. #Brexit preparations • Consequences for economic operators (unless the instrument between UK and EU provides differently) in case of ‘hard’ Brexit because UK is no longer “Union” so • Manufacturer in UK is not in Union, needs importer and AR for EU • Importer and AR for EU purposes cannot be based there • UK can not / no longer have notified bodies • For current directives (AIMDD, MDD, IVDD) • For MDR and IVDR • Transition to EU27 NB before withdrawal date (end March 2019) • All CE certificates granted by UK notified bodies will be invalid in the EU per withdrawal date because European law ceases to apply and UK notifications of notified bodies become void • Unsure if CAMD orphaning procedure applies to this
  • 27. Third party parts, components and repacking/relabeling
  • 28. Third parties: parts & components Article 23 MDR / 20 IVDR: “1. Any natural or legal person who makes available on the market an article intended specifically to replace an identical or similar integral part or component of a device that is defective or worn in order to maintain or re-establish the function of the device without changing its performance or safety characteristics or its intended purpose, shall ensure that the article does not adversely affect the safety and performance of the device. Supporting evidence shall be kept available to the competent authorities of the Member States. 2. An article that is intended specifically to replace a part or component of a device and that significantly changes the performance or safety characteristics or the intended purpose of the device shall be considered as a device and shall meet the requirements laid down in this Regulation.
  • 29. Third parties: parts & components • Non-OEM replacement parts and components must have supporting evidence that they do not adversely affect the safety and performance of the device • Standard of supporting evidence? Criterion presumes a validation • Is OEM obliged to cooperate in validation? • Non-OEM enhancement parts are devices • How will that work in practice? – accessory type evaluation? • Is manufacturer obliged to development of supporting evidence for competing non-OEM parts/components? • Printer cartridge competition law cases
  • 30. Third parties: repacking & relabelling • Basically pharma repacking case law written down for devices • Strangely enough stricter regime than outcome of the EU Court Servoprax case (C-277/15) • Article 16 (2) MDR / 15 (2) IVDR: • Translation of IFU and other information and repacking do not make someone a manufacturer • Indicated person responsible for activity on the pack or accompanying document • Have notified body blessed QMS and vigilance for activity • But blessed under what standard / CS / criteria? • Reporting and mock-up to manufacturer and NCA for each time repacked / relabelled device is made available
  • 31. Thanks for your attention! Erik Vollebregt Axon Lawyers Piet Heinkade 183 1019 HC Amsterdam T +31 88 650 6500 M +31 6 47 180 683 E erik.vollebregt@axonlawyers.com @meddevlegal B http://medicaldeviceslegal.com READ MY BLOG: http://medicaldeviceslegal.com
  • 32. Bonus slides on EO agreement drafting and negotiation
  • 33. Major overlaps in EO obligations for example in PMS and vigilance • Account for overlaps in your supply, distribution, agency, etc. agreements Post-Market Surveillance (PMS) & Vigilance EU MFR Non-EU MFR AR Importer Distributor Complaint communication within supply chain Keep register of complaints, non-conforming devices complaints, recalls, withdrawals Inform manufacturer, AR, importer about device non-conformity Vigilance System Vigilance Reporting2 Provide documentation demonstrating device compliance to Competent Authority (CA) Provide product samples free of charge to CA Provide information on serious risks of device to authorities Provide Notified Body with information on serious risk devices Implement FSCAs Cooperation with authorities on FSCAs
  • 34. Overlaps in conformity obligations Device conformity MFR Non-EU MFR AR Importer Distributor QMS pursuant to MDR / IVDR (Article 10 (9)) Person responsible for regulatory compliance QMS according to Article 16 (3) 2nd subparagraph as applicable Ensure proper device storage and transport Conformity assessment including CE-certificate Verification of appropriate conformity assessment procedure Verify CE-marking Keep copy of CE-certificate UDI assignment Verify UDI assignment Draw up Technical Documentation and keep it available 10/15 years Verification of Technical Documentation availability Keep copy of Technical Documentation Draw up of Declaration of Conformity and keep it available 10/15 years Verification of availability of Declaration of Conformity Keep Declaration of Conformity available • More sets of overlaps like this, e.g. in labeling, UDI and (product) liability
  • 35. What must be looked at in IMP agreement from MDR perspective? • Verification obligations • How to implement verification obligations? • Define when the IMP has considers or has reason to believe that a device is not in conformity with MDR requirements • Can MFR intervene / be informed before IMP notifies authorities of device presents a serious risk or is a falsified device? • Labeling and registration obligations • How will IMP label? (not obscure any information on the label provided by the manufacturer) – information exchange • Work with UDI and Eudamed • Safeguard transport and storage conditions • How will IMP do this? Consequences?
  • 36. What must be looked at in IMP agreement from MDR perspective? • Register of complaints • IMP must keep a register of complaints, of non-conforming devices and of recalls and withdrawals, and provide the manufacturer, authorised representative and distributors with any information requested by them, in order to allow them to investigate complaints – how will this work in practice? • Corrective action of IMPs • When is there a serious risk that warrants IMP to notify Notified Body and CA? • What action will take IMP? What information must be given to MFR beforehand? What consequences if IMP is wrong in implementing corrective action?
  • 37. What must be looked at in IMP agreement from MDR perspective? • Vigilance obligations of IMP and information sharing • Share with MFR complaints or reports from healthcare professionals, patients or users about suspected incidents - how will that be implemented and what is IMP confidential information? • DOC and certs on file • keep a copy of the EU declaration of conformity and, if applicable, a copy of any relevant certificate, including any amendments and supplements – how does the information exchange work? • Cooperation with authorities • Importers shall cooperate with competent authorities, at the latter’s request, on any action taken to eliminate / mitigate – what information and cooperation with MFR?
  • 38. What must be looked at in DIS agreement from MDR perspective? • General obligation – due care • DIS must act with due care in relation to the requirements applicable – what does this mean in terms of care vis-à-vis manufacturer? • Verification obligations • How to implement verification obligations? • Define when the DIS has considers or has reason to believe that a device is not in conformity with MDR requirements • Can MFR intervene / be informed before DIS notifies authorities of device presents a serious risk or is a falsified device? • Safeguard transport and storage conditions • How will IMP do this? Consequences?
  • 39. What must be looked at in DIS agreement from MDR perspective? • Corrective action of DIS • When is there a serious risk that warrants DIS to notify Notified Body and CA? • What action will take DIS? What information must be given to MFR beforehand? What consequences if DIS is wrong in implementing corrective action? • Vigilance obligations of DIS and information sharing • Share with MFR and IMP complaints or reports from healthcare professionals, patients or users about suspected incidents - how will that be implemented and what is DIS confidential information?
  • 40. What must be looked at in DIS agreement from MDR perspective? • Cooperation with authorities • Importers shall cooperate with competent authorities, at the latter’s request, on any action taken to eliminate / mitigate – what information and cooperation with MFR? • Registration obligations, traceability and UDI • How will MFR and DIS cooperate ‘to achieve an appropriate level of traceability of devices’ • National registration obligations (transfer of registrations etc)
  • 41. Review your distribution agreements • Good clause / bad clause? • Hint: drafted in the assumption that the distributor does not have any autonomous obligations